RNAC — Cartesian Therapeutics Income Statement
0.000.00%
- $480.67m
- $377.25m
- $26.00m
Annual income statement for Cartesian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.68 | 16.6 | 85.1 | 111 | 26 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 59.1 | 73.9 | 89.7 | 96.2 | 112 |
Operating Profit | -52.5 | -57.3 | -4.6 | 14.5 | -86.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -55.4 | -68.9 | -9.72 | 34.8 | -239 |
Provision for Income Taxes | |||||
Net Income After Taxes | -55.4 | -68.9 | -25.7 | 35.4 | -220 |
Net Income Before Extraordinary Items | |||||
Net Income | -55.4 | -68.9 | -25.7 | 35.4 | -220 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -55.4 | -68.9 | -25.7 | 35.4 | -220 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -36.5 | -20.3 | -6.74 | 7.28 | -42.4 |